Drug intelligence / Profile preview

Temozolomide + Tovorafenib

Development stage: Unknown
Lead developer: Day One Biopharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

The combination of temozolomide and tovorafenib is an investigational treatment approach for certain types of gliomas. Temozolomide is an FDA-approved chemotherapy drug commonly used in the treatment of gliomas, particularly glioblastoma. Tovorafenib (also known as DAY101, formerly TAK-580, MLN2480) is an investigational, oral, highly selective, CNS-penetrant, small molecule, type II pan-RAF inhibitor being studied for pediatric low-grade gliomas and other tumors with RAF alterations.

Targets

ARAF (Proto-oncogene serine/threonine-protein kinase A-Raf)BRAF (B-Raf proto-oncogene, serine/threonine kinase)RAF1 (c-Raf-1 (Y340D/Y341D))DNA

Beyond the preview

Go deeper on Temozolomide + Tovorafenib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Temozolomide + Tovorafenib.

Explore the full profile